- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01804010
Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers
- To assess the pharmacokinetic profile of ivabradine (S 16257) and its main active metabolite S 18982 in Korean healthy volunteers after oral administration of ivabradine at the doses of 2.5, 5, 10mg and after repeated oral administrations of ivabradine for 4.5 days at the same doses twice daily versus placebo and to use the study results for bridging with Caucasian data.
- The pharmacodynamic profile of ivabradine versus placebo by measuring its effects on heart rate after single and then after repeated administrations.
- Clinical safety of ivabradine versus placebo.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Seoul, Corée, République de, 138-736
- Asan Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- age between 18 and 40 years and Korean
- Nonsmoker or smoke less than 5 cigarettes per day
- normal dietary habits
- BMI ranging from 18 to 25 kg/m2
- good physical and mental status, determined by the investigator
- vital signs in resting condition within range: SBP 100-139 mmHg, DBP 50-89 mmHg
- Normal ECG
Exclusion Criteria:
- Participate any other trial in the last 3 months prior to the study
- History of major psychiatric, medical, surgical disorders
- Acute, or chronic disease
- History of hypersensitivity to at least one drug
- History of alcoholism or positive alcohol breath test
- Positive drug screening results
- known positive serology for HIV1, HIV2, hepatitis B or C
- blood donor within the last 3 month of the study
- regular use of sedatives, hypnotics, tranquillisers
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Placebo
Administration du placebo
|
Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg).
Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
Autres noms:
|
Comparateur actif: Ivabradine
Single and repeated oral administrations of 3 doses of ivabradine
|
Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg).
Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Cmax,tmax, AUC(Area under the time-concentration curve) of ivabradine and metabolite
Délai: within 60 days after blood sampling (blood sample analysis)
|
For PK measurements, blood samplings were done: pre-dose then 20 min, 40 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h, 60 h, and 72 h following the D1 single administration (P1) and the Day 8 (D8) last repeated dose (P2), respectively.Ivabradine and its main metabolite were determined using LC-MS/MS, then pharmacokinetic parameters were calculated by noncompartmental approach.
Descriptive statistics were performed on the PK individual parameters calculated from the plasma concentration-time profiles.
|
within 60 days after blood sampling (blood sample analysis)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
pharmacodynamics: The change of heart rate between baseline and over 24-hour, diurnal, nocturnal, awake, and asleep periods after administration of ivabradine
Délai: within 10 days after administration
|
For PD measurements, 24-hour Holter recordings were performed on Day0, Day1, Day8, and Day10. a resting 12-lead ECG were also performed. The changes of heart rate between day 1 and baseline values, between day 8 and baseline values were studied over 24-hour, diurnal, nocturnal, awake and asleep period for each ivabradine dose in comparison with placebo. Descriptive statistics by dose were performed and confidence intervals of the differences between each dose of ivabradine and placebo were constructed using a non-parametric method based on Hodges & Lehman estimate for independent samples. |
within 10 days after administration
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 2007-0114
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Personne en bonne santé
-
AstraZenecaParexelComplété
Essais cliniques sur Ivabradine and placebo
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)ComplétéDémence | Maladie d'Alzheimer | Membres de la famille | Épuisement professionnel des soignantsÉtats-Unis
-
hearX GroupUniversity of PretoriaComplété
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRecrutementDémence | Déficience cognitive légère | Démence mixte | Démence de type Alzheimer | Déficience cognitive subjective | Démence SénileSuède
-
University of Illinois at ChicagoRecrutementPersonnes âgées en bonne santéÉtats-Unis
-
Vastra Gotaland RegionDetectivio ABComplété
-
University of South CarolinaActif, ne recrute pasFrénésie alimentaire | L'image corporelle | Comportement alimentaire | Nutrition, Santé | Alimentation désordonnéeÉtats-Unis
-
National University of MalaysiaComplétéApplications mobilesMalaisie
-
Institut de Cancérologie de la LoireComplété
-
University of Illinois at Urbana-ChampaignInconnueBlessure de chute | Prévention des chutes | Sécurité antichute
-
Samsung ElectronicsComplétéVieilli | Adultes | Moyen-Âge | Âgé, 80 ans et plusCorée, République de